Gilead Sciences Inc (NASDAQ:GILD)

71.52
Delayed Data
As of Jun 21
 +0.06 / +0.08%
Today’s Change
64.27
Today|||52-Week Range
89.54
-0.17%
Year-to-Date
CRISPR Science and Stocks: Knowing Enough to Invest
Jun 20 / Zacks.com - Paid Partner Content
NASH Space in Focus as Galmed (GLMD) Posts Positive Data
Jun 14 / Zacks.com - Paid Partner Content
Small-Cap Biotechs Developing Novel Gene Therapies Could Become Targets of Big Pharma
Jun 20 / GuruFocus News - Paid Partner Content
Drug Stocks: The Next Hot Industry or Value Traps?
Jun 13 / Zacks.com - Paid Partner Content
Revisiting Gilead Sciences
Jun 20 / GuruFocus News - Paid Partner Content
Galmed (GLMD) Soars on Positive NASH Data on Aramchol
Jun 13 / Zacks.com - Paid Partner Content
Novartis Announces Positive Data on CAR-T Therapy, Kymriah
Jun 18 / Zacks.com - Paid Partner Content
JAK Inhibitors' Prospects Strong: 4 Stocks Ruling the Space
Jun 11 / Zacks.com - Paid Partner Content
Zacks Value Investor Highlights: Gilead Sciences, Biogen, Celgene, Lannett and Valean...
Jun 15 / Zacks.com - Paid Partner Content
 

Today’s Trading

Previous close71.46
Today’s open71.47
Day’s range70.78 - 71.69
Volume6,548,370
Average volume (3 months)7,295,951
Market cap$87.2B
Data as of 4:15pm ET, 06/21/2018

Growth & Valuation

Earnings growth (last year)-64.69%
Earnings growth (this year)-30.28%
Earnings growth (next 5 years)-3.45%
Revenue growth (last year)-13.79%
P/E ratio27.2
Price/Sales3.62
Price/Book4.29

Competitors

 Today’s
change
Today’s
% change
AMGNAmgen-0.52-0.28%
BIIBBiogen+0.48+0.16%
ILMNIllumina Inc-1.60-0.56%
----
Data as of 4:00pm ET, 06/21/2018

Financials

Next reporting dateJuly 25, 2018
EPS forecast (this quarter)$1.55
Annual revenue (last year)$26.1B
Annual profit (last year)$4.6B
Net profit margin17.71%

Profile

Sector
Health Technology
Industry
Biotechnology
President, Chief Executive Officer &
Director
John F. Milligan
CFO, Principal Accounting Officer &
Executive VP
Robin L. Washington
Corporate headquarters
Foster City, California

Forecasts